Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Intermittent Claudication Market Grown from 2024 to 2025?

The market size for intermittent claudication has experienced notable growth in the past few years. It is projected to increase from $12.81 billion in 2024 to $13.64 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. The growth during the historical period can be credited to an uptick in peripheral artery disease, heightened awareness about vascular diseases, an expanding elderly population, improved diagnosis rates, and a surge in healthcare spending.

What Growth Rate Is Anticipated for the Intermittent Claudication Market in the Coming Years?

In the coming years, the intermittent claudication market is anticipated to witness significant expansion. It’s projected to reach a value of $17.39 billion in 2029, with a 6.2% compound annual growth rate (CAGR). The predicted increase during the forecast period is due to factors such as an upsurge in diabetes cases, a rise in obesity, escalating incidences of cardiovascular diseases, an increase in the intake of alcohol and tobacco, and heightened healthcare expenditure. Major developments expected within the forecast timeframe include advancements in pad diagnostics, use of wearable technology, the inclusion of personalized medicine, a shift towards using drug-eluting stents, and progress in stem cell therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

Who Are the Leading Companies in the Intermittent Claudication Market?

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.

What Are the Key Drivers of the Intermittent Claudication Market?

The growth of the intermittent claudication market is projected to be driven by the rising occurrences of peripheral artery disease (PAD). This circulatory condition occurs when narrowed arteries hinder proper blood flow to the limbs, potentially leading to pain, numbness, and other complications. The surge in PAD cases can be linked to various factors such as an older population, diabetes, smoking, hypertension, obesity, and a lack of physical activity. PAD leads to intermittent claudication as it restricts blood supply to the leg muscles during physical activities, resulting in pain and cramping due to a lack of oxygen. For example, the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, stated in June 2023 that PAD affects between 7-12 million people in the U.S. and around 200 million worldwide. Hence, the growing instances of PAD are propelling the expansion of the intermittent claudication market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

What Are the Key Market Segments in the Intermittent Claudication Industry?

The intermittent claudication market covered in this report is segmented –

1) By Type: Medication Therapies, Revascularization

2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration

3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline

2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

What Are the Latest Trends in the Intermittent Claudication Market?

Leading organizations in the intermittent claudication market are concentrating on pioneering medication therapies like RIPK1 inhibitors, with an aim to boost the treatment results for patients afflicted with peripheral artery disease (PAD) mixed with intermittent claudication. They intend to better the blood circulation, minimize inflammation, and stave off the progression of the disease. RIPK1 inhibitors are specialized drugs designed to counteract the activity of RIPK1 kinase, thereby reducing inflammation and cell mortality. For example, in August 2022, GenFleet, a biotech company based in China, was granted approval by the US Food and Drug Administration (FDA) to undertake a Phase II clinical trial for GFH312, a novel therapy for peripheral artery disease (PAD) combined with intermittent claudication (IC). This study, which is randomized, double-blinded, and placebo-controlled, will take place across 15 research centers. GFH312 is a RIPK1 inhibitor that has demonstrated potential in early studies by diminishing inflammatory response in animal models.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

What Are the Key Regional Markets in the Intermittent Claudication Industry?

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

This Report Delivers Insight On:

1. How big is the intermittent claudication market, and how is it changing globally?

2. Who are the major companies in the intermittent claudication market, and how are they performing?

3. What are the key opportunities and risks in the intermittent claudication market right now?

4. Which products or customer segments are growing the most in the intermittent claudication market?

5. What factors are helping or slowing down the growth of the intermittent claudication market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model